IPOGrid
0002079272
IPO filing research
Lakewood-Amedex Biotherapeutics Inc.
Pharmaceutical Preparations · LABT
follow-on
trading
effective
Nasdaq Capital Market
EFFECT
Lakewood-Amedex Biotherapeutics Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: EFFECT on 2026-09-24. Current deal snapshot: exchange Nasdaq Capital Market.
Filing Timeline
SEC EDGAR
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
2026-09-24 · 9999999995-26-003056
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows S-1/A in the pre-IPO sequence.
4,512,400 shares
Class A · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds No proceeds received by the company
Lakewood-Amedex Biotherapeutics Inc. is preparing for its IPO, highlighting significant risks associated with its clinical trials and regulatory approval processes. The company faces challenges in demonstrating the safety and efficacy of its product candidates, with potential delays and failures in clinical trials impacting its ability to secure regulatory approvals. The filing emphasizes the uncertainty of clinical outcomes, regulatory hurdles, and the financial implications of these risks, including increased development costs and potential market entry delays.
2026-09-18 · 0001213900-26-101512
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Lakewood-Amedex Biotherapeutics Inc. reports significant increases in operating expenses, particularly in research and development (up 242% to $503K for Q3 2026) and general/administrative costs (up 571% to $3.3M), driven by expansion as a public company, compliance costs, and Series C financing. Net loss widened to $3.77M for Q3 2026, with improved liquidity from $6.8M in Series C proceeds and conversion of preferred stock. The company remains loss-making with $2.6M cash balances as of June 2026.
2026-08-24 · 0001213900-26-092773
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
937,500 shares · Gross proceeds $7,500,000
Series C · Exchange NASDAQ · Ticker LABT · Warrant to purchase 3,379 shares · Use of proceeds Repaid short-term debt and strengthened balance sheet
Lakewood-Amedex Biotherapeutics Inc. reported unaudited quarterly financial results for the period ended June 30, 2026, showing a net loss of $4.7 million for the six months ended June 30, 2026. The company completed a Series C Convertible Preferred Stock financing raising $6.8 million, repaid short-term notes, and converted outstanding debt into common stock. The company's common stock trades on Nasdaq under the ticker LABT, and a reverse stock split was implemented. Liquidity concerns persist due to historical losses and reliance on financing.
2026-08-17 · 0001213900-26-090808
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
17,506,577 shares
common stock, par value $0.0001 per share · Exchange Nasdaq · Ticker LABT
Lakewood-Amedex Biotherapeutics Inc. updated its prospectus with a Form 8-K filing detailing a 1-for-10 reverse stock split effective June 19, 2026, reducing outstanding shares from ~17.5 million to ~1.75 million. The company also announced a new CUSIP number (51255A201) for its common stock. The reverse stock split adjusts equity awards, preferred stock, and warrants, while reducing authorized shares to 12.5 million. The filing emphasizes ongoing clinical trials for its lead product Nu-3, targeting diabetic foot ulcers, but highlights significant liquidity challenges with a $2.8 million stockholders' deficit and $3.03 million in current liabilities.
2026-06-22 · 0001213900-26-070622
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows DRS/A and confirms the priced prospectus.
Common Stock, par value $0.0001 per share · Exchange Nasdaq · Ticker LABT
The current filing updates the prospectus for Lakewood-Amedex Biotherapeutics Inc. with information from the Company's June 15, 2026, Form 8-K report, including details about a 1-for-10 reverse stock split effective June 19, 2026. The supplement clarifies that the reverse stock split reduces the number of outstanding shares and adjusts equity awards, warrants, and authorized shares. The Company's common stock will continue trading under the ticker LABT on Nasdaq with a new CUSIP number.
2026-06-22 · 0001213900-26-070620
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows DRS and confirms the priced prospectus.
Gross proceeds $7,500,000
Series C · Exchange NASDAQ · Ticker LABT
Lakewood-Amedex Biotherapeutics Inc. reported a net loss of $923,291 for Q1 2026, with negative cash flow from operations and significant liquidity challenges. The company disclosed a $7.5 million Series C Convertible Preferred Stock offering in April 2026, which improved short-term liquidity, but ongoing operations beyond Q4 2026 will require additional capital. The company also completed its Nasdaq listing in April 2026, resulting in conversions of convertible debt and preferred stock into common shares. Financial statements highlight declining cash reserves, growing liabilities, and continued losses, raising substantial doubt about the company's ability to continue as a going concern.
2026-05-26 · 0001213900-26-061019
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
First tracked pre-IPO filing for this issuer.
Gross proceeds $7,500,000
Common Stock · Exchange NASDAQ · Ticker LABT · Use of proceeds To improve liquidity and fund operations
Lakewood-Amedex Biotherapeutics Inc. reported significant liabilities, a large accumulated deficit, and ongoing liquidity challenges in its Q1 2026 financials. The company completed a $7.5M Series C preferred stock offering and listed on Nasdaq in April 2026, converting existing preferred shares and debt into common stock. Despite these actions, substantial doubt remains about its ability to continue as a going concern due to historical losses, negative cash flow, and reliance on future financing. The company is advancing clinical trials for its lead product Nu-3 but requires additional capital to sustain operations beyond 2026.
2026-05-26 · 0001213900-26-061018
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows DRS and confirms the priced prospectus.
9,647,726 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds No proceeds received by the issuer; selling stockholders are the ones receiving proceeds
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing anti-infective therapies. The company has not yet received regulatory approval for any product candidates and faces significant risks in clinical development, regulatory approval, and commercialization. Key challenges include the high failure rate of clinical trials, dependence on third-party payors for reimbursement, and the need for substantial additional capital to fund operations. The company emphasizes its limited operating history, unproven product candidates, and the uncertainties of the drug development process.
2026-05-14 · 0001213900-26-056648
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
2026-05-13 · 9999999995-26-001622
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
9,647,726 shares · Gross proceeds $0.00
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds from the sale of the shares.
Lakewood-Amedex Biotherapeutics Inc. is a biotechnology company focused on developing antimicrobial therapies to combat antibiotic-resistant bacterial strains, including MRSA and VRE. The company is registering 9,647,726 shares of common stock for resale by selling stockholders, including RBW Capital Partners LLC and an investor selling stockholder. The offering includes shares from a private placement and compensation for advisory services. The company is an emerging growth company with no proceeds going to it directly. Clinical trials for its lead product, Nu-3, are ongoing, with plans for Phase 2a/2b studies to determine optimal dosing for commercialization.
2026-05-01 · 0001213900-26-050936
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
First tracked pre-IPO filing for this issuer.
Exchange Nasdaq Stock Market LLC · Ticker LABT · 33,784 warrants to purchase common stock at $10.00 per share
The current 424B3 filing updates the prospectus for Lakewood-Amedex Biotherapeutics Inc. to include information from the company's April 28, 2026 Form 8-K. The update focuses on the appointment of Dr. Joseph Tucker to the Board of Directors, his compensation structure, and related agreements. This follows the previous 424B4 filing, which outlined the company's direct listing plans and private placement of Series C Preferred Stock.
2026-04-30 · 0001213900-26-050264
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
First tracked pre-IPO filing for this issuer.
4,689,177 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Series C Preferred Stock convertible into Common Stock at a variable price · Selling stockholders only · Use of proceeds Proceeds from the sale of shares by Registered Stockholders are not received by the company
Lakewood-Amedex Biotherapeutics Inc. is conducting a direct listing on Nasdaq, allowing registered stockholders to resell up to 4,689,177 shares of common stock without a traditional IPO underwriting. The company engaged RBW Capital Partners as a financial advisor and placement agent for the listing and a private placement of Series C Preferred Stock. The direct listing structure, lack of underwriting, and reliance on a novel price-setting mechanism introduce unique risks. The company also plans to register shares underlying Series C Preferred Stock post-listing.
2026-04-23 · 0001213900-26-047113
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
The current filing is a Confidential Submission (CERT) for Lakewood-Amedex Biotherapeutics Inc., following a previous Notice of Effectiveness (EFFECT) on April 17, 2026. The filings indicate the company is progressing toward a potential public offering, though specific details about the offering terms, financials, or business updates are not discernible from the provided text due to formatting issues or encryption.
2026-04-22 · 0001354457-26-000363
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
Lakewood-Amedex Biotherapeutics Inc. has filed an S-1 registration statement for its initial public offering (IPO), effective April 17, 2026. The filing incorporates by reference the prospectus from the company's S-1 registration statement (File No. 333-292664), which was initially filed on January 9, 2026. The previous 8-A12B filing focused on registering common stock for listing on Nasdaq, while the current S-1 represents the formal IPO registration.
2026-04-17 · 9999999995-26-001238
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
First tracked pre-IPO filing for this issuer.
Lakewood-Amedex Biotherapeutics Inc. is registering its common stock for listing on Nasdaq via a direct listing, not an underwritten IPO. The filing incorporates by reference the S-1 registration statement, confirming the company's intent to list without traditional underwriting. The registration is under Section 12(b) of the Exchange Act, with no exhibits required as no other securities are registered on Nasdaq.
2026-04-17 · 0001213900-26-045037
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
4,689,177 shares · Gross proceeds $0.00
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds
Lakewood-Amedex Biotherapeutics Inc. is conducting a direct listing on Nasdaq, enabling existing stockholders to resell up to 4,689,177 shares of common stock without a traditional IPO. The company has engaged RBW Capital Partners as a financial advisor and placement agent for a Series C Preferred Stock private placement. The listing depends on Nasdaq approval, with shares initially priced via a novel 'Current Reference Price' mechanism. The company also plans to file a resale registration for Series C Preferred Stock and Advisory Shares post-listing.
2026-04-06 · 0001213900-26-040254
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
4,689,177 shares · Gross proceeds $0.00
Common · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds Proceeds from the resale will not be received by the company · Flags self_underwritten · Underwriters self-underwritten
Lakewood-Amedex Biotherapeutics Inc. is undergoing a direct listing on Nasdaq, allowing existing shareholders to resell up to 4,689,177 shares of common stock without a traditional underwritten offering. The company has engaged RBW Capital Partners as a financial advisor and placement agent for its Series C Preferred Stock private placement. The listing process involves a novel price-setting mechanism by Nasdaq, with risks including market volatility and dependency on Nasdaq approval. The company also plans to file a resale registration for Series C Preferred Stock and Advisory Shares post-listing.
2026-04-01 · 0001213900-26-037938
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
4,689,177 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds
Lakewood-Amedex Biotherapeutics Inc. is registering the resale of up to 4,689,177 shares of common stock by existing shareholders for a direct listing on Nasdaq, bypassing a traditional IPO. The company has engaged RBW Capital Partners LLC as a financial advisor and placement agent for the direct listing and a private placement of Series C Preferred Stock. The filing highlights risks related to the Nasdaq listing approval, stock price volatility, and the company's status as an emerging growth company with reduced reporting requirements.
2026-03-11 · 0001213900-26-026195
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
4,689,177 shares · Gross proceeds $0.00
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds Proceeds from the resale will go to the selling stockholders; no proceeds to the company
Lakewood-Amedex Biotherapeutics Inc. is registering shares for a direct listing on Nasdaq, allowing existing shareholders to resell up to 4,689,177 common shares without a traditional IPO. The company has engaged RBW Capital Partners as a financial advisor and placement agent for a private placement of Series C Preferred Stock. The direct listing process involves Nasdaq's price-setting mechanism, with no underwriting. The company is an emerging growth company with reduced reporting requirements, and the listing is contingent on Nasdaq approval.
2026-02-13 · 0001213900-26-015814
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
4,689,177 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Series C Preferred Stock convertible into Common Stock at specified terms · Selling stockholders only · Use of proceeds Proceeds from resale go to stockholders; no issuer proceeds · Underwriters self-underwritten
Lakewood-Amedex Biotherapeutics Inc. is registering the resale of up to 4,689,177 shares of common stock by existing shareholders for a direct listing on Nasdaq, bypassing a traditional IPO. The company engaged RBW Capital Partners as financial advisor and placement agent for the listing and a private placement of Series C Preferred Stock. The offering is contingent on Nasdaq approval, with no assurance of success. The company is an emerging growth company with reduced reporting requirements.
2026-02-05 · 0001213900-26-012492
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
4,689,177 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker LABT · Selling stockholders only · Use of proceeds No proceeds received by the issuer; resale by stockholders · Flags self_underwritten · Underwriters self-underwritten
Lakewood-Amedex Biotherapeutics Inc. is registering shares for a direct listing on Nasdaq, involving 4,689,177 common shares resold by existing stockholders. The offering includes a private placement of Series C Preferred Stock convertible into common shares and compensation of 269,411 advisory shares to RBW Capital Partners. The company is an emerging growth company with reduced reporting requirements, and the direct listing lacks underwriting, relying on Nasdaq's price-setting mechanism.
2026-01-09 · 0001213900-26-003037
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
Lakewood-Amedex Biotherapeutics Inc. is proceeding with a direct listing on Nasdaq, registering up to 3,897,723 shares of common stock for resale by existing stockholders. The offering involves a novel approach without a firm-commitment underwriting, relying instead on Nasdaq's price-setting mechanism. The company has engaged RBW Capital Partners as a financial advisor and placement agent for a private placement of Series C Preferred Stock, convertible into common stock. The listing is conditional on Nasdaq approval, with risks including market volatility and uncertainty in the listing process.
2025-10-17 · 0001213900-25-100021
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Lakewood-Amedex Biotherapeutics Inc. is registering shares of common stock for a direct listing on Nasdaq, involving resale by existing stockholders without a traditional underwritten offering. The company has engaged RBW Capital Partners as a financial advisor for the listing process. The filing highlights risks related to Nasdaq approval, stock price volatility, and the company's limited operating history. No public market exists for the stock, and the direct listing structure introduces uncertainties compared to traditional IPOs.
2025-07-31 · 0001213900-25-070092
Comparable Deals
20 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 20 using nearest neighbors.
Showing top 8 by similarity.
ADARx Pharmaceuticals, Inc.
ADRX
same SICrecent IPO
Vogenx, Inc.
VOGX
same SICrecent IPO
BlossomHill Therapeutics, Inc.
BLSM
same SICrecent IPO
Latigo Biotherapeutics, Inc.
LTGO
same SICrecent IPO
Braveheart Bio, Inc.
BRVE
same SICrecent IPO
Apnimed, Inc.
APMD
same SICrecent IPO
Kardigan, Inc.
KARD
same SICrecent IPO
Parabilis Medicines, Inc.
PBLS
same SICrecent IPO
Recent News
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
bing.com · 2026-04-23T08:59:00.000Z